Recursion Pharmaceuticals Posts $74.7M Revenue and Secures $134M Sanofi Milestone
Recursion Pharmaceuticals generated $74.7 million in 2025 revenue, up from $58.8 million in 2024, driven by milestone and collaboration payments. The REC-4881 program achieved a 43% median reduction in polyp burden after 12 weeks and the Sanofi partnership reached $134 million in payments, extending the cash runway into early 2028.
1. 2025 Financial Performance
Recursion Pharmaceuticals recorded $74.7 million in total revenue for 2025, up from $58.8 million in 2024, driven by milestone achievements and collaboration payments across its partnerships.
2. Clinical Progress on REC-4881
The company’s REC-4881 program targeting Familial Adenomatous Polyposis achieved a 43% median reduction in total polyp burden after 12 weeks in clinical evaluation, marking a key validation of its AI-driven discovery platform.
3. Collaboration Milestones and Cash Runway
Recursion reached its fifth milestone on the Sanofi collaboration, triggering $134 million in payments and bringing cumulative upfront and milestone revenues from all partnerships to over $500 million, which extended its cash runway into early 2028.
4. 2026 Pipeline Focus
For 2026, the company plans to advance five differentiated clinical candidates, expects early Phase 1 data for REC-1245 and REC-7735, and aims to engage the FDA in H1 2026 to define a registration path for its FAP program.